Liminatus Pharma, Inc. Class A Common Stock (LIMN) — Net Asset Momentum
Liminatus Pharma, Inc. Class A Common Stock (LIMN) recorded a net asset momentum of 38.2% as of December 2025, with net assets of $-9.81 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore Liminatus Pharma, Inc. Class A Common St cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
YoY Momentum
Current Net Assets
Years of Data
Country
Liminatus Pharma, Inc. Class A Common Stock Net Asset Momentum (2021–2025)
This chart tracks Liminatus Pharma, Inc. Class A Common Stock's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +38.2%, with net assets of $-9.81 Million USD as of December 2025. See Liminatus Pharma, Inc. Class A Common St free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Annual Net Asset History for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below shows the complete annual net asset history for Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see Liminatus Pharma, Inc. Class A Common St (LIMN) market capitalisation.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $-9.81 Million | $512.79K | $10.33 Million | ▲ +38.2% |
| 2024 | $-15.87 Million | $2.83 Million | $18.70 Million | ▼ -48.4% |
| 2023 | $-10.69 Million | $4.50 Million | $15.19 Million | ▼ -926.2% |
| 2022 | $1.29 Million | $15.49 Million | $14.19 Million | ▼ -99.5% |
| 2021 | $254.87 Million | $276.44 Million | $21.57 Million | — |